Spring Bank Pharmaceuticals Inc (SBPH) Expected to Post Earnings of -$0.55 Per Share

Wall Street analysts forecast that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will post earnings per share (EPS) of ($0.55) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Spring Bank Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.86). Spring Bank Pharmaceuticals posted earnings of ($0.51) per share during the same quarter last year, which would indicate a negative year over year growth rate of 7.8%. The business is scheduled to issue its next quarterly earnings results on Wednesday, February 21st.

According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($2.70) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($1.75). For the next year, analysts expect that the business will post earnings of ($2.16) per share, with EPS estimates ranging from ($3.62) to ($1.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Spring Bank Pharmaceuticals.

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald set a $29.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 16th. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, November 6th. B. Riley assumed coverage on shares of Spring Bank Pharmaceuticals in a research report on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, ValuEngine lowered shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $27.25.

A number of large investors have recently added to or reduced their stakes in SBPH. AXA bought a new position in Spring Bank Pharmaceuticals during the second quarter worth about $2,894,000. Sectoral Asset Management Inc bought a new position in Spring Bank Pharmaceuticals during the second quarter worth about $1,523,000. C WorldWide Group Holding A S increased its position in Spring Bank Pharmaceuticals by 342.6% during the third quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock worth $1,873,000 after acquiring an additional 86,077 shares during the period. Morse Asset Management Inc increased its position in Spring Bank Pharmaceuticals by 94.7% during the third quarter. Morse Asset Management Inc now owns 124,000 shares of the company’s stock worth $2,004,000 after acquiring an additional 60,300 shares during the period. Finally, Vanguard Group Inc. bought a new position in Spring Bank Pharmaceuticals during the second quarter worth about $794,000. 29.70% of the stock is currently owned by institutional investors and hedge funds.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) traded up $0.56 on Monday, hitting $12.66. 34,500 shares of the stock traded hands, compared to its average volume of 51,014. The company has a market capitalization of $163.18 and a price-to-earnings ratio of -4.59. Spring Bank Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $18.93.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.truebluetribune.com/2018/01/11/spring-bank-pharmaceuticals-inc-sbph-expected-to-post-earnings-of-0-55-per-share.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply